JP2016527920A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016527920A5 JP2016527920A5 JP2016536482A JP2016536482A JP2016527920A5 JP 2016527920 A5 JP2016527920 A5 JP 2016527920A5 JP 2016536482 A JP2016536482 A JP 2016536482A JP 2016536482 A JP2016536482 A JP 2016536482A JP 2016527920 A5 JP2016527920 A5 JP 2016527920A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccinia virus
- oncolytic vaccinia
- deletion
- virus
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000700618 Vaccinia virus Species 0.000 claims description 44
- 230000000174 oncolytic effect Effects 0.000 claims description 43
- 230000004048 modification Effects 0.000 claims description 40
- 238000012986 modification Methods 0.000 claims description 40
- 238000012217 deletion Methods 0.000 claims description 32
- 230000037430 deletion Effects 0.000 claims description 32
- 230000013595 glycosylation Effects 0.000 claims description 26
- 238000006206 glycosylation reaction Methods 0.000 claims description 26
- 102000039446 nucleic acids Human genes 0.000 claims description 26
- 108020004707 nucleic acids Proteins 0.000 claims description 26
- 150000007523 nucleic acids Chemical class 0.000 claims description 26
- 241000700605 Viruses Species 0.000 claims description 20
- 230000035772 mutation Effects 0.000 claims description 16
- 230000003612 virological effect Effects 0.000 claims description 15
- 101000595548 Homo sapiens TIR domain-containing adapter molecule 1 Proteins 0.000 claims description 12
- 102100036073 TIR domain-containing adapter molecule 1 Human genes 0.000 claims description 12
- 108010051913 15-hydroxyprostaglandin dehydrogenase Proteins 0.000 claims description 10
- 102100030489 15-hydroxyprostaglandin dehydrogenase [NAD(+)] Human genes 0.000 claims description 10
- 230000005867 T cell response Effects 0.000 claims description 10
- 206010062016 Immunosuppression Diseases 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 230000001506 immunosuppresive effect Effects 0.000 claims description 8
- 230000000694 effects Effects 0.000 claims description 7
- 239000005557 antagonist Substances 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 claims description 6
- 229960002986 dinoprostone Drugs 0.000 claims description 6
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 6
- 230000007482 viral spreading Effects 0.000 claims description 6
- 101150074766 C12L gene Proteins 0.000 claims description 4
- 102220508636 Liprin-beta-1_C12L_mutation Human genes 0.000 claims description 4
- 101150009018 SPI-1 gene Proteins 0.000 claims description 4
- 238000010348 incorporation Methods 0.000 claims description 4
- 210000004027 cell Anatomy 0.000 claims description 3
- 101150108168 A33R gene Proteins 0.000 claims description 2
- 101150076005 A36R gene Proteins 0.000 claims description 2
- 101150023320 B16R gene Proteins 0.000 claims description 2
- 102220477045 Dynein axonemal assembly factor 10_A56R_mutation Human genes 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims description 2
- 101150039660 HA gene Proteins 0.000 claims description 2
- 102000003996 Interferon-beta Human genes 0.000 claims description 2
- 108090000467 Interferon-beta Proteins 0.000 claims description 2
- 101100316831 Vaccinia virus (strain Copenhagen) B18R gene Proteins 0.000 claims description 2
- 101100000236 Vaccinia virus (strain Western Reserve) VACWR159 gene Proteins 0.000 claims description 2
- 101100004099 Vaccinia virus (strain Western Reserve) VACWR200 gene Proteins 0.000 claims description 2
- 230000001093 anti-cancer Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000002955 immunomodulating agent Substances 0.000 claims description 2
- 229940121354 immunomodulator Drugs 0.000 claims description 2
- 230000010354 integration Effects 0.000 claims description 2
- 229960001388 interferon-beta Drugs 0.000 claims description 2
- 102000014909 interleukin-1 receptor activity proteins Human genes 0.000 claims description 2
- 108040006732 interleukin-1 receptor activity proteins Proteins 0.000 claims description 2
- 102000044166 interleukin-18 binding protein Human genes 0.000 claims description 2
- 108010070145 interleukin-18 binding protein Proteins 0.000 claims description 2
- 230000035755 proliferation Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 230000004614 tumor growth Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 230000004075 alteration Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361868978P | 2013-08-22 | 2013-08-22 | |
| US61/868,978 | 2013-08-22 | ||
| PCT/US2014/052308 WO2015027163A1 (en) | 2013-08-22 | 2014-08-22 | Immuno-oncolytic therapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019133264A Division JP7021154B2 (ja) | 2013-08-22 | 2019-07-19 | 免疫腫瘍溶解療法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016527920A JP2016527920A (ja) | 2016-09-15 |
| JP2016527920A5 true JP2016527920A5 (cg-RX-API-DMAC10.html) | 2017-09-28 |
| JP6912199B2 JP6912199B2 (ja) | 2021-08-04 |
Family
ID=52484194
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536482A Active JP6912199B2 (ja) | 2013-08-22 | 2014-08-22 | 免疫腫瘍溶解療法 |
| JP2019133264A Active JP7021154B2 (ja) | 2013-08-22 | 2019-07-19 | 免疫腫瘍溶解療法 |
| JP2022015459A Active JP7333431B2 (ja) | 2013-08-22 | 2022-02-03 | 免疫腫瘍溶解療法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019133264A Active JP7021154B2 (ja) | 2013-08-22 | 2019-07-19 | 免疫腫瘍溶解療法 |
| JP2022015459A Active JP7333431B2 (ja) | 2013-08-22 | 2022-02-03 | 免疫腫瘍溶解療法 |
Country Status (28)
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2847305T3 (es) | 2013-08-22 | 2021-08-02 | Univ Pittsburgh Commonwealth Sys Higher Education | Terapias inmunooncolíticas |
| EP4122492A1 (en) | 2015-02-25 | 2023-01-25 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| KR20180006916A (ko) | 2015-04-17 | 2018-01-19 | 메모리얼 슬로안-케터링 캔서 센터 | 고형 종양에 대한 면역치료제로서 mva 또는 mva델타e3l의 용도 |
| US10370647B2 (en) * | 2015-07-22 | 2019-08-06 | National University Corporation Tottori University | Host regulatory factor that enhances replication and/or propagation of vaccinia virus |
| HK1255192A1 (zh) * | 2015-09-08 | 2019-08-09 | Sillajen, Inc. | 表达细胞因子和羧酸酯酶的修饰的溶瘤痘苗病毒及其使用方法 |
| US20190038713A1 (en) | 2015-11-07 | 2019-02-07 | Multivir Inc. | Compositions comprising tumor suppressor gene therapy and immune checkpoint blockade for the treatment of cancer |
| CN109152815B (zh) | 2016-02-25 | 2022-10-18 | 纪念斯隆凯特琳癌症中心 | 用于癌症免疫治疗的具有胸苷激酶缺失和具有或不具有人flt3l或gm-csf表达的复制型减毒痘苗病毒 |
| WO2017147554A2 (en) | 2016-02-25 | 2017-08-31 | Memorial Sloan-Kettering Cancer Center | Recombinant mva or mvadele3l expressing human flt3l and use thereof as immuno-therapeutic agents against solid tumors |
| EP3432863A4 (en) * | 2016-03-25 | 2019-11-13 | University of Pittsburgh - of The Commonwealth System of Higher Education | SYNTHETICALLY COVED VIRUS |
| EP3254692A1 (en) | 2016-06-10 | 2017-12-13 | Ceva Sante Animale | Multivalent recombinant spv |
| CA3070146A1 (en) * | 2016-07-19 | 2018-01-25 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Oncolytic viruses targeting stat3 |
| JP2019528753A (ja) * | 2016-09-21 | 2019-10-17 | スティーブン エイチ． ソーン， | 高移動度グループｂｏｘｉ突然変異体 |
| GB201616365D0 (en) * | 2016-09-27 | 2016-11-09 | Helsingin Yliopisto | Non-genetic modification of enveloped viruses |
| WO2018111902A1 (en) | 2016-12-12 | 2018-06-21 | Multivir Inc. | Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases |
| CA3052463A1 (en) * | 2017-02-03 | 2018-08-09 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Oncolytic virus therapy |
| US12566181B2 (en) | 2017-03-06 | 2026-03-03 | Immunofree, Inc. | Methods and compositions for determining the potency of a therapeutic cellular composition |
| CN118892540A (zh) * | 2017-04-21 | 2024-11-05 | 新罗杰股份有限公司 | 溶瘤痘苗病毒与免疫检查点抑制剂联合疗法 |
| CN111107872A (zh) | 2017-05-12 | 2020-05-05 | 纪念斯隆-凯特林癌症中心 | 有用于癌症免疫疗法的牛痘病毒突变体 |
| WO2019089755A1 (en) | 2017-10-31 | 2019-05-09 | Western Oncolytics Ltd. | Platform oncolytic vector for systemic delivery |
| US11633441B2 (en) | 2017-12-01 | 2023-04-25 | Gerd Sutter | Immuno-modulated replication-efficient vaccinia virus strain |
| SG11202006457YA (en) * | 2018-01-05 | 2020-08-28 | Ottawa Hospital Res Inst | Modified orthopoxvirus vectors |
| CA3094329A1 (en) | 2018-03-19 | 2020-02-20 | Multivir Inc. | Methods and compositions comprising tumor suppressor gene therapy and cd122/cd132 agonists for the treatment of cancer |
| CN112739374A (zh) * | 2018-07-20 | 2021-04-30 | 安迅生物制药公司 | 唾液酸酶向癌细胞、免疫细胞和肿瘤微环境的递送 |
| CA3112654A1 (en) | 2018-09-15 | 2020-03-19 | Memorial Sloan Kettering Cancer Center | Recombinant poxviruses for cancer immunotherapy |
| CN113454231A (zh) * | 2018-12-21 | 2021-09-28 | 渥太华医院研究所 | 修饰的正痘病毒载体 |
| KR20210113632A (ko) * | 2019-01-07 | 2021-09-16 | 칼리버 임뮤노쎄라퓨틱스, 인크. | 암을 치료하는 방법 |
| US11529402B2 (en) * | 2019-01-14 | 2022-12-20 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| US11685904B2 (en) | 2019-02-14 | 2023-06-27 | Ignite Immunotherapy, Inc. | Recombinant vaccinia virus and methods of use thereof |
| JP7326663B2 (ja) * | 2019-08-26 | 2023-08-16 | バイオノックス インコーポレイテッド | がんの処置のための活性成分としてワクシニアウイルス及びヒドロキシ尿素を含む医薬組成物 |
| KR20220082025A (ko) * | 2019-10-16 | 2022-06-16 | 칼리버 임뮤노쎄라퓨틱스, 인크. | 변형된 세포외 외피보유 바이러스 |
| CN114786715A (zh) * | 2019-11-20 | 2022-07-22 | 匹兹堡大学联邦系统高等教育 | 痘苗病毒和使用痘苗病毒的方法 |
| WO2021113644A1 (en) | 2019-12-05 | 2021-06-10 | Multivir Inc. | Combinations comprising a cd8+ t cell enhancer, an immune checkpoint inhibitor and radiotherapy for targeted and abscopal effects for the treatment of cancer |
| BR112022011158A2 (pt) * | 2019-12-12 | 2022-08-30 | Ignite Immunotherapy Inc | Vírus vaccinia oncolítico variante e métodos de uso do mesmo |
| MX2022008547A (es) * | 2020-01-09 | 2022-08-10 | Pfizer | Virus de vacuna recombinante. |
| KR20220152250A (ko) * | 2020-03-06 | 2022-11-15 | 유니버시티 오브 피츠버그-오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 | 암을 치료하기 위한 irf 모듈레이터를 발현하는 종양용해성 바이러스 |
| CN116096906A (zh) * | 2020-06-29 | 2023-05-09 | 旗舰创业创新五公司 | 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途 |
| JP2023552289A (ja) | 2020-11-19 | 2023-12-15 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 腫瘍微小環境リモデリングによる腫瘍溶解性免疫療法 |
| EP4329786A4 (en) | 2021-04-30 | 2024-12-11 | KaliVir Immunotherapeutics, Inc. | Oncolytic viruses for modified mhc expression |
| US20240316104A1 (en) * | 2021-06-29 | 2024-09-26 | Flagship Pioneering Innovations V, Inc. | Immune cells engineered to promote thanotransmission and uses thereof |
| WO2023106839A1 (ko) * | 2021-12-07 | 2023-06-15 | 재단법인 아산사회복지재단 | Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도 |
| EP4551240A1 (en) * | 2022-07-08 | 2025-05-14 | Viromissile, Inc. | Oncolytic vaccinia viruses and recombinant viruses and methods of use thereof |
| WO2025251079A1 (en) * | 2024-05-31 | 2025-12-04 | University Of Massachusetts | Rna compositions and methods of use thereof in the treatment of cancer |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX9305855A (es) | 1992-09-24 | 1995-01-31 | Tadatsugu Taniguchi | Factores 1 y 2 reguladores del interferon en el diagnostico de latumorigenicidad. |
| AU5446700A (en) | 1999-05-28 | 2000-12-18 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| JP3986439B2 (ja) | 2001-02-07 | 2007-10-03 | 中外製薬株式会社 | 造血器腫瘍の治療剤 |
| WO2004014314A2 (en) * | 2002-08-12 | 2004-02-19 | David Kirn | Methods and compositions concerning poxviruses and cancer |
| WO2007023725A1 (ja) * | 2005-08-25 | 2007-03-01 | Yokohama City University | 遺伝子ワクチン |
| EP1933857A2 (en) | 2005-09-07 | 2008-06-25 | Jennerex Biotherapeutics ULC | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| US8980246B2 (en) * | 2005-09-07 | 2015-03-17 | Sillajen Biotherapeutics, Inc. | Oncolytic vaccinia virus cancer therapy |
| AU2012244210B2 (en) * | 2005-09-07 | 2014-10-02 | Sillajen Biotherapeutics, Inc. | Systemic treatment of metastatic and/or systemically-disseminated cancers using gm-csf-expressing poxviruses |
| KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| US20110038843A1 (en) * | 2008-03-31 | 2011-02-17 | Kusmartsev Sergei A | Tumor Growth Inhibition Via Conditioning of Tumor Microenvironment |
| KR101838472B1 (ko) | 2009-09-14 | 2018-03-15 | 신라젠(주) | 종양 용해 백시니아 바이러스 병용 암 치료요법 |
| WO2011119925A2 (en) * | 2010-03-25 | 2011-09-29 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthetic herpes simplex viruses for treatment of cancers |
| EP2697368B1 (en) * | 2011-04-15 | 2019-06-05 | Genelux Corporation | Clonal strains of attenuated vaccinia viruses and methods of use thereof |
| US20150250837A1 (en) * | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| ES2847305T3 (es) | 2013-08-22 | 2021-08-02 | Univ Pittsburgh Commonwealth Sys Higher Education | Terapias inmunooncolíticas |
-
2014
- 2014-08-22 ES ES14837931T patent/ES2847305T3/es active Active
- 2014-08-22 PE PE2016000287A patent/PE20160673A1/es unknown
- 2014-08-22 KR KR1020167006785A patent/KR102389240B1/ko active Active
- 2014-08-22 CA CA3213715A patent/CA3213715A1/en active Pending
- 2014-08-22 MD MD20160027A patent/MD4624C1/ro active IP Right Grant
- 2014-08-22 ES ES20189155T patent/ES2971528T3/es active Active
- 2014-08-22 EP EP20189155.3A patent/EP3778897B1/en active Active
- 2014-08-22 CA CA3213683A patent/CA3213683A1/en active Pending
- 2014-08-22 EP EP23215391.6A patent/EP4324918A3/en not_active Withdrawn
- 2014-08-22 JP JP2016536482A patent/JP6912199B2/ja active Active
- 2014-08-22 SM SM20240047T patent/SMT202400047T1/it unknown
- 2014-08-22 PT PT201891553T patent/PT3778897T/pt unknown
- 2014-08-22 SG SG11201600960PA patent/SG11201600960PA/en unknown
- 2014-08-22 WO PCT/US2014/052308 patent/WO2015027163A1/en not_active Ceased
- 2014-08-22 HU HUE20189155A patent/HUE066593T2/hu unknown
- 2014-08-22 LT LTEP20189155.3T patent/LT3778897T/lt unknown
- 2014-08-22 DK DK14837931.6T patent/DK3036329T3/da active
- 2014-08-22 EA EA201690444A patent/EA037582B1/ru unknown
- 2014-08-22 MD MDA20180086A patent/MD4748C1/ro active IP Right Grant
- 2014-08-22 AU AU2014308648A patent/AU2014308648B2/en active Active
- 2014-08-22 CA CA2921041A patent/CA2921041C/en active Active
- 2014-08-22 RS RS20240082A patent/RS65104B1/sr unknown
- 2014-08-22 EP EP14837931.6A patent/EP3036329B1/en active Active
- 2014-08-22 FI FIEP20189155.3T patent/FI3778897T3/fi active
- 2014-08-22 SI SI201432060T patent/SI3778897T1/sl unknown
- 2014-08-22 HR HRP20240078TT patent/HRP20240078T1/hr unknown
- 2014-08-22 DK DK20189155.3T patent/DK3778897T3/da active
- 2014-08-22 CN CN201480058401.0A patent/CN105658795B/zh active Active
- 2014-08-22 NZ NZ716825A patent/NZ716825A/en unknown
- 2014-08-22 MX MX2016002257A patent/MX2016002257A/es unknown
- 2014-08-22 PL PL20189155.3T patent/PL3778897T3/pl unknown
-
2016
- 2016-02-07 IL IL243996A patent/IL243996A0/en unknown
- 2016-02-18 PH PH12016500329A patent/PH12016500329A1/en unknown
- 2016-02-19 US US15/048,698 patent/US11478518B2/en active Active
-
2019
- 2019-07-19 JP JP2019133264A patent/JP7021154B2/ja active Active
-
2022
- 2022-02-03 JP JP2022015459A patent/JP7333431B2/ja active Active
- 2022-09-07 US US17/939,707 patent/US12514888B2/en active Active
-
2024
- 2024-01-30 CY CY20241100073T patent/CY1126587T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20240078T1 (hr) | Imuno-onkolitičke terapije | |
| Davola et al. | Oncolytic viruses: how “lytic” must they be for therapeutic efficacy? | |
| Guse et al. | Oncolytic vaccinia virus for the treatment of cancer | |
| Zeh et al. | Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers | |
| Everts et al. | Replication-selective oncolytic viruses in the treatment of cancer | |
| CN101868546B (zh) | 痘病毒溶瘤载体 | |
| JP2016028035A5 (cg-RX-API-DMAC10.html) | ||
| Keller et al. | Oncolytic viruses—immunotherapeutics on the rise | |
| JP2021500932A5 (cg-RX-API-DMAC10.html) | ||
| EA201690545A1 (ru) | Онколитические аденовирусы, несущие гетерологичные гены | |
| Pease et al. | Oncolytic viral therapy for mesothelioma | |
| Deng et al. | An oncolytic vaccinia virus armed with GM-CSF and IL-24 double genes for cancer targeted therapy | |
| JP2014207903A5 (cg-RX-API-DMAC10.html) | ||
| Kolluri et al. | Mesenchymal stem cells as vectors for lung cancer therapy | |
| Yang et al. | Progress in gene therapy using oncolytic vaccinia virus as vectors | |
| WO2012116636A1 (zh) | 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用 | |
| Kochneva et al. | Oncolytic poxviruses | |
| WO2009101149A3 (en) | Anti-tumour effective paramyxovirus | |
| CN108261426A (zh) | 药物组合物及其在治疗肿瘤和/或癌症的药物中的应用 | |
| Li et al. | Oncolytic virotherapy in hepato‐bilio‐pancreatic cancer: The key to breaking the log jam? | |
| WO2016163799A3 (ko) | 2-메톡시-4-(3-(4-메톡시페닐)프로프-1-엔-1-일)페놀을 유효성분으로 하는 암의 치료용 약제학적 조성물 | |
| JP2019517262A5 (cg-RX-API-DMAC10.html) | ||
| ES2745599T3 (es) | Partículas no replicantes derivadas de rhabdovirus, y sus usos | |
| Nistal-Villan et al. | Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model | |
| JP7737141B2 (ja) | 細胞融合を誘導するワクシニアウイルス及びその利用 |